SMN1 and proximal spinal muscular atrophy: By overcoming this limitation, the NBS program would implement its diagnostic sensitivity by identifying heterozygous carriers of SMN1 deletion and consequently increase the detection of families at procreative risk of SMA, with the potential perspective of reducing the incidence and/or severity of this devastating disease in the near future.